Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms

Basit Öğe Kaydı
dc.authorid0000-0003-4056-1673
dc.contributor.authorYaghmayee, Shayan
dc.contributor.authorMoazzeni, Atefeh Sadat
dc.contributor.authorJamialahmadi, Tannaz
dc.contributor.authorKarav, Sercan
dc.contributor.authorYaribeygi, Habib
dc.contributor.authorKesharwani, Prashant
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2026-02-03T12:02:40Z
dc.date.available2026-02-03T12:02:40Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractNeuronal injury is a common complication in patients with diabetes. These injuries include a wide range of neurobehavioral complications that significantly reduce the neuronal network efficiency and quality of life in affected individuals. Currently, diabetes-induced neuronal complications are a major global health challenge, and many studies have been performed to prevent or slow their progression. Semaglutide is a novel form of glucagon-like peptide-1 (GLP-1) agonist agents that has recently been approved for diabetic patients to normalize glucose metabolism. However, some evidence indicates that it has extra-glycemic effects in some tissues as well as in the central nervous system. This evidence suggests that semaglutide can suppress some pathophysiological pathways involved in diabetes-induced neuronal complications and thus improve neuronal network efficiency. However, there is limited evidence to support all the pathways involved in mediating these benefits. In the current review, we aim to present the latest clinical and experimental findings on the possible benefits of semaglutide on major neuronal complications and to determine the possible molecular mechanisms involved.
dc.identifier.doi10.1016/j.neuroscience.2025.06.009
dc.identifier.endpage197
dc.identifier.issn0306-4522
dc.identifier.issn1873-7544
dc.identifier.pmid40494410
dc.identifier.scopus2-s2.0-105007762349
dc.identifier.scopusqualityQ1
dc.identifier.startpage187
dc.identifier.urihttps://doi.org/10.1016/j.neuroscience.2025.06.009
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34811
dc.identifier.volume579
dc.identifier.wosWOS:001510724400005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofNeuroscience
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectDiabetes mellitus
dc.subjectSemaglutide
dc.subjectGLP-1
dc.subjectAlzheimer disease
dc.subjectCognition
dc.titleNeuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu